http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 29 May 2026 08:03:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html <p><b>Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time </b></p> <p align="justify">BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=M9y7XaB230vLeLB1SIx5BcmPcNk9tNu_ihz4oKTSzxdEb2UV4JM_H29nBbQagKJ17tc1Y9ZjmKuTYT1_RkY82bqCQ3TK45CdAHUA_eecDkD5kmLNSml4lUl1WlQ_uo7y" rel="nofollow" target="_blank">Bioxytran Inc.</a> (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.</p> <p align="justify">The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the http://www.streetinsider.com/Press+Releases/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html Fri, 29 May 2026 08:03:00 -0400 A.06822034 BIXT O.07604345 O.20026344 http://www.streetinsider.com/Press+Releases/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html <p><b>Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time </b></p> <p align="justify">BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=M9y7XaB230vLeLB1SIx5BcmPcNk9tNu_ihz4oKTSzxdEb2UV4JM_H29nBbQagKJ17tc1Y9ZjmKuTYT1_RkY82bqCQ3TK45CdAHUA_eecDkD5kmLNSml4lUl1WlQ_uo7y" rel="nofollow" target="_blank">Bioxytran Inc.</a> (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.</p> <p align="justify">The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the http://www.streetinsider.com/Press+Releases/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html Fri, 29 May 2026 08:03:00 -0400 A.06822034 BIXT O.07604345 O.20026344 http://www.streetinsider.com/Press+Releases/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html <p><b>Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time </b></p> <p align="justify">BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=M9y7XaB230vLeLB1SIx5BcmPcNk9tNu_ihz4oKTSzxdEb2UV4JM_H29nBbQagKJ17tc1Y9ZjmKuTYT1_RkY82bqCQ3TK45CdAHUA_eecDkD5kmLNSml4lUl1WlQ_uo7y" rel="nofollow" target="_blank">Bioxytran Inc.</a> (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.</p> <p align="justify">The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the http://www.streetinsider.com/Press+Releases/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html Fri, 29 May 2026 08:03:00 -0400 A.06822034 BIXT O.07604345 O.20026344 http://www.streetinsider.com/Press+Releases/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html <p><b>Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time </b></p> <p align="justify">BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=M9y7XaB230vLeLB1SIx5BcmPcNk9tNu_ihz4oKTSzxdEb2UV4JM_H29nBbQagKJ17tc1Y9ZjmKuTYT1_RkY82bqCQ3TK45CdAHUA_eecDkD5kmLNSml4lUl1WlQ_uo7y" rel="nofollow" target="_blank">Bioxytran Inc.</a> (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.</p> <p align="justify">The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the http://www.streetinsider.com/Press+Releases/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html Fri, 29 May 2026 08:03:00 -0400 A.06822034 BIXT O.07604345 O.20026344 http://www.streetinsider.com/Globe+Newswire/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html <p><b>Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time </b></p> <p align="justify">BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=M9y7XaB230vLeLB1SIx5BcmPcNk9tNu_ihz4oKTSzxdEb2UV4JM_H29nBbQagKJ17tc1Y9ZjmKuTYT1_RkY82bqCQ3TK45CdAHUA_eecDkD5kmLNSml4lUl1WlQ_uo7y" rel="nofollow" target="_blank">Bioxytran Inc.</a> (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.</p> <p align="justify">The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the http://www.streetinsider.com/Globe+Newswire/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html Fri, 29 May 2026 08:03:00 -0400 A.06822034 BIXT O.07604345 O.20026344 http://www.streetinsider.com/Globe+Newswire/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html <p><b>Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time </b></p> <p align="justify">BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=M9y7XaB230vLeLB1SIx5BcmPcNk9tNu_ihz4oKTSzxdEb2UV4JM_H29nBbQagKJ17tc1Y9ZjmKuTYT1_RkY82bqCQ3TK45CdAHUA_eecDkD5kmLNSml4lUl1WlQ_uo7y" rel="nofollow" target="_blank">Bioxytran Inc.</a> (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.</p> <p align="justify">The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the http://www.streetinsider.com/Globe+Newswire/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html Fri, 29 May 2026 08:03:00 -0400 A.06822034 BIXT O.07604345 O.20026344 http://www.streetinsider.com/Globe+Newswire/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html <p><b>Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time </b></p> <p align="justify">BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=M9y7XaB230vLeLB1SIx5BcmPcNk9tNu_ihz4oKTSzxdEb2UV4JM_H29nBbQagKJ17tc1Y9ZjmKuTYT1_RkY82bqCQ3TK45CdAHUA_eecDkD5kmLNSml4lUl1WlQ_uo7y" rel="nofollow" target="_blank">Bioxytran Inc.</a> (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.</p> <p align="justify">The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the http://www.streetinsider.com/Globe+Newswire/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html Fri, 29 May 2026 08:03:00 -0400 A.06822034 BIXT O.07604345 O.20026344 http://www.streetinsider.com/Globe+Newswire/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html <p><b>Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time </b></p> <p align="justify">BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=M9y7XaB230vLeLB1SIx5BcmPcNk9tNu_ihz4oKTSzxdEb2UV4JM_H29nBbQagKJ17tc1Y9ZjmKuTYT1_RkY82bqCQ3TK45CdAHUA_eecDkD5kmLNSml4lUl1WlQ_uo7y" rel="nofollow" target="_blank">Bioxytran Inc.</a> (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.</p> <p align="justify">The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the http://www.streetinsider.com/Globe+Newswire/Bioxytran+Highlights+New+Book+on+Real-Time+Monitoring+Tissue+Oxygenation+Relevant+to+Oxygen+Carrier+BXT-25/26570928.html Fri, 29 May 2026 08:03:00 -0400 A.06822034 BIXT O.07604345 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+31/26503305.html si-local-file:///var/storage/secattach/20260515/26503305.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+31/26503305.html Fri, 15 May 2026 13:29:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+31/26503305.html si-local-file:///var/storage/secattach/20260515/26503305.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+31/26503305.html Fri, 15 May 2026 13:29:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Dec+31/26318292.html si-local-file:///var/storage/secattach/20260415/26318292.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Dec+31/26318292.html Wed, 15 Apr 2026 16:02:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Dec+31/26318292.html si-local-file:///var/storage/secattach/20260415/26318292.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Dec+31/26318292.html Wed, 15 Apr 2026 16:02:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++BIOXYTRAN%2C+INC++++++++++++For%3A+Dec+31/26254383.html si-local-file:///var/storage/secattach/20260401/26254383.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++BIOXYTRAN%2C+INC++++++++++++For%3A+Dec+31/26254383.html Wed, 01 Apr 2026 06:24:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++BIOXYTRAN%2C+INC++++++++++++For%3A+Dec+31/26254383.html si-local-file:///var/storage/secattach/20260401/26254383.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++BIOXYTRAN%2C+INC++++++++++++For%3A+Dec+31/26254383.html Wed, 01 Apr 2026 06:24:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+20/26195739.html si-local-file:///var/storage/secattach/20260320/26195739.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+20/26195739.html Fri, 20 Mar 2026 09:05:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+20/26195739.html si-local-file:///var/storage/secattach/20260320/26195739.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+20/26195739.html Fri, 20 Mar 2026 09:05:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+12/26159402.html si-local-file:///var/storage/secattach/20260313/26159402.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+12/26159402.html Fri, 13 Mar 2026 16:00:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+12/26159402.html si-local-file:///var/storage/secattach/20260313/26159402.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+12/26159402.html Fri, 13 Mar 2026 16:00:00 -0400 BIXT O.07604345 http://www.streetinsider.com/FDA/Bioxytran+reports+positive+results+from+COVID-19+antiviral+trial/26089583.html <p>Bioxytran Inc. (OTCQB: BIXT) announced results from a Phase 1b/2a clinical study of its oral antiviral drug ProLectin-M in hospitalized patients with mild to moderate COVID-19. The randomized, double-blind, placebo-controlled study enrolled 39 participants in India.</p> <p>The study showed that patients receiving the highest dose of ProLectin-M at 16,800 mg per day achieved statistically significant earlier viral clearance compared to placebo. By Day 5, 90% of participants in the highest-dose group achieved non-detectable viral shedding, compared to 20% in the placebo group. The difference was statistically significant with a p-value of 0.001.</p> <p>Clinical improvement also occurred faster in the highest-dose group, with http://www.streetinsider.com/FDA/Bioxytran+reports+positive+results+from+COVID-19+antiviral+trial/26089583.html Mon, 02 Mar 2026 11:40:11 -0400 BIXT http://www.streetinsider.com/Press+Releases/Bioxytran%2C+Inc.+Reports+Positive+Phase+1b2a+Clinical+Study+Results+for+ProLectin-M%2C+a+Broad-Range+Antiviral+Drug+in+Mild+to+Moderate+COVID-19+/26089582.html <p><strong id="dateline">BOSTON, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 2, 2026 / </strong>Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2.</p><p>The study showed that the highest evaluated dose of ProLectin-M (16,800 mg/day) was associated with statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared with placebo, while demonstrating a favorable safety and tolerability profile. By Day 7, viral clearance was observed across all http://www.streetinsider.com/Press+Releases/Bioxytran%2C+Inc.+Reports+Positive+Phase+1b2a+Clinical+Study+Results+for+ProLectin-M%2C+a+Broad-Range+Antiviral+Drug+in+Mild+to+Moderate+COVID-19+/26089582.html Mon, 02 Mar 2026 11:40:00 -0400 BIXT http://www.streetinsider.com/ACCESS+Newswire/Bioxytran%2C+Inc.+Reports+Positive+Phase+1b2a+Clinical+Study+Results+for+ProLectin-M%2C+a+Broad-Range+Antiviral+Drug+in+Mild+to+Moderate+COVID-19+/26089582.html <p><strong id="dateline">BOSTON, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 2, 2026 / </strong>Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2.</p><p>The study showed that the highest evaluated dose of ProLectin-M (16,800 mg/day) was associated with statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared with placebo, while demonstrating a favorable safety and tolerability profile. By Day 7, viral clearance was observed across all http://www.streetinsider.com/ACCESS+Newswire/Bioxytran%2C+Inc.+Reports+Positive+Phase+1b2a+Clinical+Study+Results+for+ProLectin-M%2C+a+Broad-Range+Antiviral+Drug+in+Mild+to+Moderate+COVID-19+/26089582.html Mon, 02 Mar 2026 11:40:00 -0400 BIXT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+02/26088329.html si-local-file:///var/storage/secattach/20260302/26088329.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+02/26088329.html Mon, 02 Mar 2026 09:22:00 -0400 BIXT O.07604345 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+02/26088329.html si-local-file:///var/storage/secattach/20260302/26088329.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOXYTRAN%2C+INC++++++++++++For%3A+Mar+02/26088329.html Mon, 02 Mar 2026 09:22:00 -0400 BIXT O.07604345 http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran&apos;s novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 -0400 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989 http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html <p>BOSTON, Massachusetts, Feb 23, 2026 - (JCN Newswire) - - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.</p><p>The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran&apos;s novel galectin antagonist as a potential therapeutic for infected poultry . The research is http://www.streetinsider.com/Press+Releases/Bioxytran+Initiates+Research+Collaboration+with+University+of+Georgia+to+Evaluate+Drug+Candidate%26apos%3Bs+Ability+to+Block+H5N1+Bird+Flu+Virus/26039713.html Mon, 23 Feb 2026 06:00:00 -0400 A.11845204 A.34662575 A.40538608 BIXT O.00092932 O.02096384 O.07604345 O.16070989